Licensing Agreement, Agreement Extension Term

No definition available.

Name:	jazz_LicensingAgreementAgreementExtensionTerm
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Exclusivity Grace Period

+ References

No definition available.

+ Details

Name:	jazz_LossContingencyExclusivityGracePeriod
Namespace Prefix:	jazz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Number Of Additional New Drug Applications Approved

+ References

No definition available.

+ Details

Name:	jazz_LossContingencyNumberOfAdditionalNewDrugApplicationsApproved
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Litigation Cases After Consolidation

+ References

No definition available.

+ Details

Name:	jazz_NumberOfLitigationCasesAfterConsolidation
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Patents Covered In Instructions

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPatentsCoveredInInstructions
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Patents Deemed Unenforceable

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPatentsDeemedUnenforceable
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of patents named in petitions for inter partes review (IPR).

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPatentsNamedInInterPartesReviewIPRPetitions
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Petition Claims Denied Under Patent

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPetitionClaimsDeniedUnderPatent
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Petition Claims Under Patent Review

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPetitionClaimsUnderPatentReview
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Petition Claims Under Patent Review Deemed Unpatentable

+ References

No definition available.

+ Details

Name:	jazz_NumberOfPetitionClaimsUnderPatentReviewDeemedUnpatentable
Namespace Prefix:	jazz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of claims settled.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyClaimsSettledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=jazz_XyremMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=jazz_AmnealPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=jazz_OhmLaboratoriesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=jazz_ErwinazeAndErwinaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=jazz_DefitelioDefibrotideMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=jazz_XyremANDAMattersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company and Summary of Significant Accounting Policies - Significant Risks and Uncertainties Additional Information (Details) $ in Thousands		1 Months Ended				3 Months Ended		6 Months Ended
	Apr. 05, 2017	Mar. 31, 2017 claim_under_petition	Jul. 31, 2016 patent	Mar. 31, 2016 claim_under_petition	Apr. 30, 2015 litigation_case	Jun. 30, 2017 USD ($) company	Jun. 30, 2016 USD ($) lawsuit	Jun. 30, 2017 USD ($) patent company	Jun. 30, 2016 USD ($) litigation_case	Jan. 19, 2017 application
Concentration Risk [Line Items]
Product sales, net \| $						$ 389,655	$ 379,110	$ 763,333	$ 713,026
Number of DDI patents covered in instructions \| patent								3
Xyrem
Concentration Risk [Line Items]
Product sales, net \| $						$ 298,026	$ 280,968	$ 570,352	530,505
Number of ANDAs filed by third parties \| company						8		8
Exclusivity grace period	6 months
Number of claims settled \| lawsuit							2
Number of claims under IPR review				3
Number of ANDAs approved \| application										2
Xyrem \| Pending Litigation
Concentration Risk [Line Items]
Number of patents deemed unenforceable by PTAB \| patent			6
Number of petition claims PTAB denied				25
Number of petition claims under patent review				28
Number of petition claims under patent review deemed unpatentable		3
Xyrem \| Amneal Pharmaceuticals
Concentration Risk [Line Items]
Number of ANDAs approved \| application										1
Xyrem \| Ohm Laboratories Inc.
Concentration Risk [Line Items]
Number of ANDAs approved \| application										1
Xyrem \| Product Concentration Risk \| Sales Revenue, Product Line
Concentration Risk [Line Items]
Percentage of product sales, net (as a percent)						76.00%		75.00%
Erwinaze and Erwinase
Concentration Risk [Line Items]
Product sales, net \| $						$ 49,024	$ 49,748	$ 100,412	$ 100,921
Licensing agreement extension term								5 years
Erwinaze and Erwinase \| Product Concentration Risk \| Sales Revenue, Product Line
Concentration Risk [Line Items]
Percentage of product sales, net (as a percent)						13.00%		13.00%
Defitelio/Defibrotide \| Product Concentration Risk \| Sales Revenue, Product Line
Concentration Risk [Line Items]
Percentage of product sales, net (as a percent)						8.00%		9.00%
Xyrem ANDA Matters \| Pending Litigation
Concentration Risk [Line Items]
Number of litigation cases after consolidation \| litigation_case					1				1